高中性脂肪血症:治療薬開発パイプライン動向(2016年下半期版)

Global Markets Directが発行した調査報告書(DATA70209380)
◆英語タイトル:Hypertriglyceridemia - Pipeline Review, H2 2016
◆商品コード:DATA70209380
◆発行会社(リサーチ会社):Global Markets Direct
◆発行日:2016年12月30日
◆ページ数:113
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD2,000 ⇒換算¥226,000見積依頼/購入/質問フォーム
Site LicenseUSD4,000 ⇒換算¥452,000見積依頼/購入/質問フォーム
Enterprisewide (Global Site License)USD6,000 ⇒換算¥678,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。Global Markets Direct社の概要及び新刊レポートはこちらでご確認いただけます。

当調査レポートでは、世界における高中性脂肪血症の治療薬開発パイプライン動向について調査・分析し、企業で開発中の治療薬、大学/研究機関で研究中の治療薬、後期段階の製品、治験段階の製品、初期段階の製品、単剤治療薬/併用治療薬/標的別/作用機序別/投与経路別/分子の種類別治療薬の評価、各薬剤のプロファイル(説明、作用機序、研究開発の進展状況)などのデータをお届けいたします。
・イントロダクション
・高中性脂肪血症の概要
・高中性脂肪血症治療薬の開発
  - パイプライン製品の概要
  - パイプライン製品の比較分析
・企業で開発中の治療薬
・大学/研究機関で研究中の治療薬
・高中性脂肪血症パイプライン製品の概略
  - 後期段階の製品
  - 治験段階の製品
  - 初期段階の製品
・企業別、開発中の製品
・大学/研究機関別、研究中の製品
・高中性脂肪血症治療薬開発に取り組んでいる企業:企業別製品パイプライン
・高中性脂肪血症治療薬の評価
  - 単剤治療薬
  - 併用治療薬
  - 標的別
  - 作用機序(MoA)別
  - 投与経路(RoA)別
  - 分子の種類別
・各薬剤のプロファイル:説明、作用機序、研究開発(R&D)の進展状況
・パイプライン製品の最新動向
・開発休止中の製品/プロジェクト
・開発が中止された製品
・製品開発のマイルストーン
【レポートの概要】

Hypertriglyceridemia – Pipeline Review, H2 2016

Summary

Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Hypertriglyceridemia – Pipeline Review, H2 2016, provides an overview of the Hypertriglyceridemia (Metabolic Disorders) pipeline landscape.

Hypertriglyceridemia is a condition in which triglyceride levels are elevated. Causes include diabetes mellitus, obesity, family history and sedentary habits. Symptoms include gastrointestinal pain, difficulty breathing, memory loss, dementia, xanthelasmas and corneal arcus. Treatment includes diuretics, beta-blockers, estrogen therapy and corticosteroids.

Report Highlights

Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Hypertriglyceridemia – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Hypertriglyceridemia (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hypertriglyceridemia (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Hypertriglyceridemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 9, 1, 2, 11 and 1 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.

Hypertriglyceridemia (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Hypertriglyceridemia (Metabolic Disorders).
- The pipeline guide reviews pipeline therapeutics for Hypertriglyceridemia (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Hypertriglyceridemia (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Hypertriglyceridemia (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Hypertriglyceridemia (Metabolic Disorders)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Hypertriglyceridemia (Metabolic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Hypertriglyceridemia (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

【レポートの目次】

Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Hypertriglyceridemia Overview 9
Therapeutics Development 10
Pipeline Products for Hypertriglyceridemia – Overview 10
Pipeline Products for Hypertriglyceridemia – Comparative Analysis 11
Hypertriglyceridemia – Therapeutics under Development by Companies 12
Hypertriglyceridemia – Therapeutics under Investigation by Universities/Institutes 14
Hypertriglyceridemia – Pipeline Products Glance 15
Late Stage Products 15
Clinical Stage Products 16
Early Stage Products 17
Hypertriglyceridemia – Products under Development by Companies 18
Hypertriglyceridemia – Products under Investigation by Universities/Institutes 19
Hypertriglyceridemia – Companies Involved in Therapeutics Development 20
Acasti Pharma Inc 20
Akcea Therapeutics Inc 21
Allergan Plc 22
Alnylam Pharmaceuticals Inc 23
Arisaph Pharmaceuticals Inc 24
AstraZeneca Plc 25
BASF SE 26
Cardax Inc 27
Catabasis Pharmaceuticals Inc 28
Celon Pharma SA 29
CymaBay Therapeutics Inc 30
Gemphire Therapeutics Inc 31
Jeil Pharmaceutical Co Ltd 32
Kyorin Pharmaceutical Co Ltd 33
LipimetiX Development Inc 34
Matinas BioPharma Holdings Inc 35
Sancilio & Company Inc 36
Zydus Cadila Healthcare Ltd 37
Hypertriglyceridemia – Therapeutics Assessment 38
Assessment by Monotherapy Products 38
Assessment by Target 39
Assessment by Mechanism of Action 41
Assessment by Route of Administration 43
Assessment by Molecule Type 45
Drug Profiles 47
AEM-28 – Drug Profile 47
Product Description 47
Mechanism Of Action 47
R&D Progress 47
AEM-2814 – Drug Profile 49
Product Description 49
Mechanism Of Action 49
R&D Progress 49
ALN-AC3 – Drug Profile 50
Product Description 50
Mechanism Of Action 50
R&D Progress 50
ALN-ANG – Drug Profile 51
Product Description 51
Mechanism Of Action 51
R&D Progress 51
Antibody to Inhibit ANGPTL4 for Hypertriglyceridemia – Drug Profile 52
Product Description 52
Mechanism Of Action 52
R&D Progress 52
ARI-3037MO – Drug Profile 53
Product Description 53
Mechanism Of Action 53
R&D Progress 53
bezafibrate SR – Drug Profile 55
Product Description 55
Mechanism Of Action 55
R&D Progress 55
BioE-1115 – Drug Profile 56
Product Description 56
Mechanism Of Action 56
R&D Progress 56
BSN-272 – Drug Profile 57
Product Description 57
Mechanism Of Action 57
R&D Progress 57
CAT-2000 Series – Drug Profile 58
Product Description 58
Mechanism Of Action 58
R&D Progress 58
CAT-2003 – Drug Profile 59
Product Description 59
Mechanism Of Action 59
R&D Progress 59
CDX-085 – Drug Profile 62
Product Description 62
Mechanism Of Action 62
R&D Progress 62
gemcabene calcium – Drug Profile 64
Product Description 64
Mechanism Of Action 64
R&D Progress 64
icosabutate – Drug Profile 67
Product Description 67
Mechanism Of Action 67
R&D Progress 67
IONIS-ANGPTL3LRx – Drug Profile 69
Product Description 69
Mechanism Of Action 69
R&D Progress 69
IONIS-APOCIIILRX – Drug Profile 70
Product Description 70
Mechanism Of Action 70
R&D Progress 70
LTPO-3FA – Drug Profile 71
Product Description 71
Mechanism Of Action 71
R&D Progress 71
MAT-9001 – Drug Profile 72
Product Description 72
Mechanism Of Action 72
R&D Progress 72
MN-002 – Drug Profile 74
Product Description 74
Mechanism Of Action 74
R&D Progress 74
NKPL-66 – Drug Profile 75
Product Description 75
Mechanism Of Action 75
R&D Progress 75
omega-3-carboxylic acids – Drug Profile 79
Product Description 79
Mechanism Of Action 79
R&D Progress 79
saroglitazar – Drug Profile 83
Product Description 83
Mechanism Of Action 83
R&D Progress 83
SC-401 – Drug Profile 85
Product Description 85
Mechanism Of Action 85
R&D Progress 85
seladelpar – Drug Profile 86
Product Description 86
Mechanism Of Action 86
R&D Progress 86
Small Molecule for Hypertriglyceridaemia – Drug Profile 89
Product Description 89
Mechanism Of Action 89
R&D Progress 89
Synthetic Peptides for Dyslipidemic and Vascular Disorders – Drug Profile 90
Product Description 90
Mechanism Of Action 90
R&D Progress 90
volanesorsen sodium – Drug Profile 91
Product Description 91
Mechanism Of Action 91
R&D Progress 91
Hypertriglyceridemia – Dormant Projects 97
Hypertriglyceridemia – Discontinued Products 99
Hypertriglyceridemia – Product Development Milestones 100
Featured News & Press Releases 100
Dec 19, 2016: Akcea and Ionis Announce Positive Results from COMPASS Phase 3 Study of Volanesorsen 100
Sep 14, 2016: Acasti Pharma Reports Positive CaPre Omega-3 Bridging Study Data 101
Jun 11, 2016: New Scientific Data of Investigational Lipaglyn (Saroglitazar), and Real World Data in Patients will be Featured at American Diabetes Association (ADA) 76th Scientific Sessions 102
May 16, 2016: Akcea Therapeutics Announces Completion of Enrollment in Phase 3 COMPASS Trial of Volanesorsen 103
Mar 23, 2016: MediciNova Receives Notice of Allowance for New Patent Covering MN-001 and MN-002 for the Treatment of Hypertriglyceridemia, Hypercholesterolemia, and Hyperlipoproteinemia 103
Feb 24, 2016: SPCI Announces US PTO Allowance of Patent Claims 104
Nov 18, 2015: Zydus announces clinical trials of Saroglitazar in patients with Severe Hypertriglyceridemia in USA 104
Jul 29, 2015: Positive Clinical Data From Volanesorsen Published in the New England Journal of Medicine 105
May 25, 2015: Phase 2a Clinical Study of Icosabutate in Patients with Severe Hypertriglyceridemia 106
Apr 22, 2015: CymaBay Therapeutics Announces U.S. Orphan Drug Designation for MBX-8025 in Severe Hypertriglyceridemia 107
Mar 02, 2015: Acasti Receives Full Data for Phase II TRIFECTA Trial 107
Sep 30, 2014: Acasti Announces Positive Top-Line Pharmacokinetic Results 108
Sep 29, 2014: Acasti Reports Successful CaPre Phase II TRIFECTA Results Proving Statistically Significant Improvements in Triglycerides & Non-HDL-C 108
Sep 02, 2014: Isis Pharmaceuticals Presents Data On ISIS-APOCIIIRX At European Society of Cardiology Congress 2014 110
Jul 24, 2014: Acasti Announces Oral Presentation on COLT Study Results at 19th World Congress on Heart Disease in Boston 110
Appendix 112
Methodology 112
Coverage 112
Secondary Research 112
Primary Research 112
Expert Panel Validation 112
Contact Us 112
Disclaimer 113

List of Tables
Number of Products under Development for Hypertriglyceridemia, H2 2016 10
Number of Products under Development for Hypertriglyceridemia - Comparative Analysis, H2 2016 11
Number of Products under Development by Companies, H2 2016 13
Number of Products under Investigation by Universities/Institutes, H2 2016 14
Comparative Analysis by Late Stage Development, H2 2016 15
Comparative Analysis by Clinical Stage Development, H2 2016 16
Comparative Analysis by Early Stage Development, H2 2016 17
Products under Development by Companies, H2 2016 18
Products under Investigation by Universities/Institutes, H2 2016 19
Hypertriglyceridemia - Pipeline by Acasti Pharma Inc, H2 2016 20
Hypertriglyceridemia - Pipeline by Akcea Therapeutics Inc, H2 2016 21
Hypertriglyceridemia - Pipeline by Allergan Plc, H2 2016 22
Hypertriglyceridemia - Pipeline by Alnylam Pharmaceuticals Inc, H2 2016 23
Hypertriglyceridemia - Pipeline by Arisaph Pharmaceuticals Inc, H2 2016 24
Hypertriglyceridemia - Pipeline by AstraZeneca Plc, H2 2016 25
Hypertriglyceridemia - Pipeline by BASF SE, H2 2016 26
Hypertriglyceridemia - Pipeline by Cardax Inc, H2 2016 27
Hypertriglyceridemia - Pipeline by Catabasis Pharmaceuticals Inc, H2 2016 28
Hypertriglyceridemia - Pipeline by Celon Pharma SA, H2 2016 29
Hypertriglyceridemia - Pipeline by CymaBay Therapeutics Inc, H2 2016 30
Hypertriglyceridemia - Pipeline by Gemphire Therapeutics Inc, H2 2016 31
Hypertriglyceridemia - Pipeline by Jeil Pharmaceutical Co Ltd, H2 2016 32
Hypertriglyceridemia - Pipeline by Kyorin Pharmaceutical Co Ltd, H2 2016 33
Hypertriglyceridemia - Pipeline by LipimetiX Development Inc, H2 2016 34
Hypertriglyceridemia - Pipeline by Matinas BioPharma Holdings Inc, H2 2016 35
Hypertriglyceridemia - Pipeline by Sancilio & Company Inc, H2 2016 36
Hypertriglyceridemia - Pipeline by Zydus Cadila Healthcare Ltd, H2 2016 37
Assessment by Monotherapy Products, H2 2016 38
Number of Products by Stage and Target, H2 2016 40
Number of Products by Stage and Mechanism of Action, H2 2016 42
Number of Products by Stage and Route of Administration, H2 2016 44
Number of Products by Stage and Molecule Type, H2 2016 46
Hypertriglyceridemia - Dormant Projects, H2 2016 97
Hypertriglyceridemia - Dormant Projects (Contd..1), H2 2016 98
Hypertriglyceridemia - Discontinued Products, H2 2016 99

List of Figures
Number of Products under Development for Hypertriglyceridemia, H2 2016 10
Number of Products under Development for Hypertriglyceridemia - Comparative Analysis, H2 2016 11
Number of Products under Development by Companies, H2 2016 12
Comparative Analysis by Clinical Stage Development, H2 2016 16
Comparative Analysis by Early Stage Products, H2 2016 17
Assessment by Monotherapy Products, H2 2016 38
Number of Products by Top 10 Targets, H2 2016 39
Number of Products by Stage and Top 10 Targets, H2 2016 39
Number of Products by Top 10 Mechanism of Actions, H2 2016 41
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 41
Number of Products by Routes of Administration, H2 2016 43
Number of Products by Stage and Routes of Administration, H2 2016 43
Number of Products by Molecule Types, H2 2016 45
Number of Products by Stage and Molecule Types, H2 2016 45

【レポートのキーワード】

高中性脂肪血症

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 高中性脂肪血症:治療薬開発パイプライン動向(2016年下半期版)(Hypertriglyceridemia - Pipeline Review, H2 2016)]についてメールでお問い合わせはこちらでお願いします。


◆H&Iグローバルリサーチのお客様(例)◆